Skip to main content
NVDA+0.21%AAPL-0.23%GOOGL+0.30%MSFT-0.42%AMZN-0.29%TSM+0.17%SPCX-4.21%META+0.03%AVGO+0.73%TSLA-0.15%BRK-B+0.61%SKHY-3.19%LLY-1.36%MU+0.27%AMD+1.90%WMT-0.71%JPM-0.86%V+1.74%XOM+1.12%ASMLa-4.20%JNJ-5.73%MA+1.63%INTC+1.44%0700.HK-0.03%ABBV-2.40%1398.HK-1.41%CSCO-0.23%CVX+1.27%COST-0.50%ORCL+4.23%KO+0.36%BAC-1.14%DELL-0.72%LRCX-2.73%AMAT-6.69%PG-0.10%AP2d-8.45%CAT-3.33%UNH-0.20%3988.HK-1.16%1816.HK-25.11%0005.HK-1.09%HSBA.L+0.17%0857.HK+0.29%GE-0.33%PM-1.34%0939.HK-1.63%1288.HK-2.19%MS-1.78%NFLX-0.21%CADCHF+0.60%GBPCHF+0.52%AUDCHF+0.46%NZDCHF+0.44%GBPTRY+0.41%USDCAD-0.40%EURCAD-0.35%GBPHKD+0.32%AUDSGD+0.31%GBPUSD+0.31%CADJPY+0.29%NZDSGD+0.29%CHFJPY-0.29%GBPMXN-0.28%USDTRY+0.28%NZDUSD+0.27%AUDUSD+0.27%USDNOK-0.26%EURCHF+0.25%EURGBP-0.23%NZDMXN+0.23%USDZAR-0.21%GBPJPY+0.21%GBPSGD+0.20%USDCHF+0.20%EURAUD-0.18%USDPLN-0.17%AUDJPY+0.17%USDSEK-0.16%EURNOK-0.16%USDILS+0.16%NZDCAD-0.16%EURNZD-0.16%CHFNOK-0.16%CHFSGD+0.16%AUDDKK+0.16%NOKJPY+0.16%SGDJPY-0.16%NZDJPY+0.15%EURSGD+0.15%AUDCAD-0.13%EURZAR-0.11%EURHKD+0.10%USDDKK-0.10%USDJPY-0.10%GBPCAD-0.08%GBPZAR-0.07%EURCNH+0.07%EURPLN-0.07%EURSEK-0.07%EURUSD+0.06%CHFSEK-0.06%PLNJPY+0.06%GBPAUD+0.06%USDSGD+0.05%GBPNZD+0.04%USDCOP-0.04%USDCNH-0.03%EURJPY-0.03%AUDNZD+0.02%USDTHB+0.02%USDMXN-0.01%EURCZK+0.01%USDHKD+0.01%AUDNOK0.00%EURDKK0.00%COTTON+0.73%HG1+0.72%S1+0.48%XNGUSD+0.32%W1-0.24%XAGUSD+0.22%GAGUSD+0.22%UKOIL-0.16%USOIL-0.14%XAUUSD+0.11%GAUUSD+0.11%XPTUSD+0.05%BTCUSD+2.42%ETHUSD+17.67%USDTUSD+0.02%XRPUSD+11.86%SOLUSD+12.05%TRXUSDT+0.77%ZECUSDT+8.52%DOGEUSD+14.12%XMRUSDT+5.79%LINKUSD+13.42%XLMUSD+0.25%BCHUSDT+5.89%UNIUSD+7.49%LTCUSD+9.66%SUIUSD+3.36%HBARUSDT+0.40%TONUSD+26.15%TAOUSDT+3.79%AAVEUSD+3.57%DOTUSDT-0.20%ICPUSDT+0.88%ONDOUSDT+0.38%WLDUSDT-0.21%ARBUSDT+6.76%JUPUSDT+0.62%ATOMUSDT+1.90%INJUSDT+13.23%STXUSDT+6.76%FETUSDT+2.77%TIAUSDT+9.19%PYTHUSDT-0.84%SEIUSDT+4.57%IMXUSDT+0.63%OPUSDT+18.94%GRTUSDT+4.09%IOTAUSDT+0.86%WIFUSDT+2.70%AXSUSDT-1.83%POLUSDT+2.78%FARTCOINUSDT+0.63%EOSUSDT+2.75%DYDXUSDT+3.35%GALAUSDT-1.87%ORDIUSDT-0.12%RONINUSDT-3.42%NOTUSDT+1.21%NVDA+0.21%AAPL-0.23%GOOGL+0.30%MSFT-0.42%AMZN-0.29%TSM+0.17%SPCX-4.21%META+0.03%AVGO+0.73%TSLA-0.15%BRK-B+0.61%SKHY-3.19%LLY-1.36%MU+0.27%AMD+1.90%WMT-0.71%JPM-0.86%V+1.74%XOM+1.12%ASMLa-4.20%JNJ-5.73%MA+1.63%INTC+1.44%0700.HK-0.03%ABBV-2.40%1398.HK-1.41%CSCO-0.23%CVX+1.27%COST-0.50%ORCL+4.23%KO+0.36%BAC-1.14%DELL-0.72%LRCX-2.73%AMAT-6.69%PG-0.10%AP2d-8.45%CAT-3.33%UNH-0.20%3988.HK-1.16%1816.HK-25.11%0005.HK-1.09%HSBA.L+0.17%0857.HK+0.29%GE-0.33%PM-1.34%0939.HK-1.63%1288.HK-2.19%MS-1.78%NFLX-0.21%CADCHF+0.60%GBPCHF+0.52%AUDCHF+0.46%NZDCHF+0.44%GBPTRY+0.41%USDCAD-0.40%EURCAD-0.35%GBPHKD+0.32%AUDSGD+0.31%GBPUSD+0.31%CADJPY+0.29%NZDSGD+0.29%CHFJPY-0.29%GBPMXN-0.28%USDTRY+0.28%NZDUSD+0.27%AUDUSD+0.27%USDNOK-0.26%EURCHF+0.25%EURGBP-0.23%NZDMXN+0.23%USDZAR-0.21%GBPJPY+0.21%GBPSGD+0.20%USDCHF+0.20%EURAUD-0.18%USDPLN-0.17%AUDJPY+0.17%USDSEK-0.16%EURNOK-0.16%USDILS+0.16%NZDCAD-0.16%EURNZD-0.16%CHFNOK-0.16%CHFSGD+0.16%AUDDKK+0.16%NOKJPY+0.16%SGDJPY-0.16%NZDJPY+0.15%EURSGD+0.15%AUDCAD-0.13%EURZAR-0.11%EURHKD+0.10%USDDKK-0.10%USDJPY-0.10%GBPCAD-0.08%GBPZAR-0.07%EURCNH+0.07%EURPLN-0.07%EURSEK-0.07%EURUSD+0.06%CHFSEK-0.06%PLNJPY+0.06%GBPAUD+0.06%USDSGD+0.05%GBPNZD+0.04%USDCOP-0.04%USDCNH-0.03%EURJPY-0.03%AUDNZD+0.02%USDTHB+0.02%USDMXN-0.01%EURCZK+0.01%USDHKD+0.01%AUDNOK0.00%EURDKK0.00%COTTON+0.73%HG1+0.72%S1+0.48%XNGUSD+0.32%W1-0.24%XAGUSD+0.22%GAGUSD+0.22%UKOIL-0.16%USOIL-0.14%XAUUSD+0.11%GAUUSD+0.11%XPTUSD+0.05%BTCUSD+2.42%ETHUSD+17.67%USDTUSD+0.02%XRPUSD+11.86%SOLUSD+12.05%TRXUSDT+0.77%ZECUSDT+8.52%DOGEUSD+14.12%XMRUSDT+5.79%LINKUSD+13.42%XLMUSD+0.25%BCHUSDT+5.89%UNIUSD+7.49%LTCUSD+9.66%SUIUSD+3.36%HBARUSDT+0.40%TONUSD+26.15%TAOUSDT+3.79%AAVEUSD+3.57%DOTUSDT-0.20%ICPUSDT+0.88%ONDOUSDT+0.38%WLDUSDT-0.21%ARBUSDT+6.76%JUPUSDT+0.62%ATOMUSDT+1.90%INJUSDT+13.23%STXUSDT+6.76%FETUSDT+2.77%TIAUSDT+9.19%PYTHUSDT-0.84%SEIUSDT+4.57%IMXUSDT+0.63%OPUSDT+18.94%GRTUSDT+4.09%IOTAUSDT+0.86%WIFUSDT+2.70%AXSUSDT-1.83%POLUSDT+2.78%FARTCOINUSDT+0.63%EOSUSDT+2.75%DYDXUSDT+3.35%GALAUSDT-1.87%ORDIUSDT-0.12%RONINUSDT-3.42%NOTUSDT+1.21%
AT

Allogene Therapeutics, Inc. (ALLO)

NASDAQ • Healthcare

$1.29
-$0.1 (-7.9%)
Market closed

Last close at October 13, 2026 at 20:00 UTC

Open$1.37
Day Range$1.29 - $1.38
Avg. Volume (3M)5.8M
Market Cap$445.2M
52 Week Range
$1.04$4.46
Next EarningsIn 22 daysNov 5, 2026

Metrics Over Time

Where the Money Goes

Q2 2026
Revenueeverything earned$4.6M100%
Gross Profitminus cost of goods$4.6M100%

Fundamentals & Financials

Revenue (TTM)
$4.6M
Net Income (TTM)
-$165.4M
EPS (TTM)
-$0.67
ROA (TTM)
-30.08%
Current Ratio
10.72

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Earnings

+32.0%Q1 2026-$0.17
+5.3%Q2 2026-$0.18
+24.1%Q3 2026-$0.13
Next

Nov 5

in 22 daysQ4 2026

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q3 2026
Beat +24.1%

Allogene Therapeutics' EPS of -$0.13 topped the -$0.17 estimate, +24%, in the fiscal second quarter of 2026 reported on August 12, as revenue and gross profit both came in at about $4.6 million. Operating loss was about $46.9 million, and net income was a loss of about $42.7 million versus a loss of about $50.9 million a year ago, +16.2% year over year; EPS was up 43.5% from -$0.23 a year earlier. For the next period, consensus calls for EPS of -$0.15 on revenue of $2,222.00.

Next report — what to expect

Allogene Therapeutics, Inc. (ALLO) reports earnings on November 5, 2026. Wall Street’s next-period consensus calls for EPS of -$0.147 on revenue of $2,500.00. Heading into the print, ALLO has beaten EPS in 7 of 8 most recent quarters, making any deviation from that pattern a key item to watch.

View full earnings history

About Allogene Therapeutics, Inc.

Allogene Therapeutics, Inc. (NASDAQ: ALLO) is a clinical-stage biotechnology company focused on immuno-oncology, developing genetically engineered allogeneic T-cell therapies for cancer. In qualitative terms, it is an early-stage biotech built around off-the-shelf cell therapy candidates for hematologic and solid tumors rather than marketed products.

Name
Allogene Therapeutics, Inc.
CEO
Zachary Roberts
Website
www.allogene.com
Industry
Healthcare
Year Founded
2017
Employees
151

Today's Snapshot

AI-generated

ALLO closed 7.9% lower at 1.29, in line with a weaker sector.

Trading Volume

Above 10d avg 5.9M

6M

vs S&P 500 Today

Strong Underperformance

-7.84%

Updated: October 13, 2026 at 20:15 UTC

ALLO Headlines

Biotech, Pharma Stocks Draw Fresh Valuation Focus

April 2, 2026

4 min read
View All News

Technical Indicators

2 Buy0 Neutral6 Sell
ALLO is firmly bearish with a strong downtrend signaled by a high ADX and negative on-balance volume, while price is well below short-, medium- and long-term moving averages and the pivot lies above the market, reinforcing resistance. Several oscillators are oversold and showing buy signals, suggesting potential for a counterparty bounce, however momentum and MACD remain negative and volatility is elevated on a percentage basis. Technical takeaway: clear strong-sell regime with oversold readings that may produce limited bounces but do not negate the dominant downtrend.
All signals
  • EMA (5 indicators)$1.45 - $1.84
    Sell
  • RSI (14)21.64
    Buy
  • Stochastic %K (14, 3, 3)13.68
    Buy
  • MACD Level (12, 26)-0.13
    Sell

Peers & Related Assets

FATEFate Therapeutics, Inc.
$2-6.1%
AUTLAutolus Therapeutics plc
IPSCCentury Therapeutics, Inc.
DTILPrecision BioSciences, Inc.
CLLSCellectis S.A.
ATRAAtara Biotherapeutics, Inc.
Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.